Effects of a Novel Hepatitis B Anti-viral Drug E-CFCP in Renal Organic Acid Transporters
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell viability and uptake assays, we examined the effects of E-CFCP on the function of renal organic anion transporters (OATs). No cytotoxicity was shown related to the E-CFCP in the renal OATs in either assay. Thus, this study suggested that E-CFCP may be a novel, excellent candidate drug for the treatment of drug-resistant HBV.
References
1.
Kaneko M, Reien Y, Morio H, Fukuuchi T, Kaneko K, Hirayama Y
. Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters. J Pharmacol Sci. 2021; 146(2):82-87.
DOI: 10.1016/j.jphs.2021.03.004.
View
2.
Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T
. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 2002; 63(1):143-55.
DOI: 10.1046/j.1523-1755.2003.00710.x.
View
3.
. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res. 2020; 50(8):892-923.
DOI: 10.1111/hepr.13504.
View
4.
Hosoyamada M, Obinata M, Suzuki M, Endou H
. Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene. Arch Toxicol. 1996; 70(5):284-92.
DOI: 10.1007/s002040050275.
View
5.
Motohashi H, Inui K
. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013; 15(2):581-8.
PMC: 3675737.
DOI: 10.1208/s12248-013-9465-7.
View